BioCryst Pharmaceuticals Files 8-K on Financials
Ticker: BCRX · Form: 8-K · Filed: Jan 10, 2025 · CIK: 882796
Sentiment: neutral
Topics: financial-condition, regulation-fd, filing
Related Tickers: BCRX
TL;DR
BioCryst dropped an 8-K on Jan 10th - mostly routine financial updates, no major news yet.
AI Summary
On January 10, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This 8-K filing provides an update on BioCryst Pharmaceuticals' operational and financial status, which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting routine financial information and disclosures, with no immediate indication of significant negative events.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- January 10, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Durham, North Carolina (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for BioCryst Pharmaceuticals?
The primary purpose of this 8-K filing is to report on BioCryst Pharmaceuticals' results of operations and financial condition, as well as Regulation FD disclosures and financial statements.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on January 10, 2025.
In which state is BioCryst Pharmaceuticals, Inc. incorporated?
BioCryst Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for BioCryst Pharmaceuticals?
The principal executive office address for BioCryst Pharmaceuticals is 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
Does this filing excerpt contain specific financial results or material events?
No, the provided excerpt of the 8-K filing does not detail specific financial results or material events; it primarily outlines the categories of information being reported.
Filing Stats: 644 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-10 07:13:22
Key Financial Figures
- $437 M — ORLADEYO (berotralstat) Net Revenue of $437 Million, (+34 percent y-o-y) " 104 Cover
Filing Documents
- f8k_011025.htm (8-K) — 16KB
- exh_991.htm (EX-99.1) — 12KB
- 0001171843-25-000155.txt ( ) — 228KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_011025_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 10, 2025, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing preliminary, unaudited ORLADEYO (berotralstat) net revenue and total revenue for the fourth quarter and full fiscal year ended December 31, 2024. The Company also provided guidance for full year 2025 ORLADEYO net revenue and total revenue, full year 2025 operating expenses, and its expectation that the Company will approach quarterly earnings per share profitability in the second half of the fiscal year ending December 31, 2025. The press release also referenced a previously announced, upcoming webcast presentation by the Company at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2025 at 6:00 p.m. ET. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated January 10, 2025 entitled " BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million, (+34 percent y-o-y) " 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioCryst Pharmaceuticals, Inc. Date: January 10, 2025 By: /s/ Alane Barnes Alane Barnes Chief Legal Officer